We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Bladder Cancer

Journal Scan / Research · January 25, 2023

Enhancing the Performance of Cxbladder Tests by Adding the Analysis of FGFR3 and TERT Gene Mutations

The Journal of Urology

 

Additional Info

The Journal of Urology
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification
J Urol 2022 Dec 30;[EPub Ahead of Print], Y Lotan, JD Raman, B Konety, S Daneshmand, F Schroeck, SF Shariat, P Black, M de Lange, S Asroff, E Goldfischer, M Efros, KT Chong, E Huang, HL Chua, QH Wu, S Yeow, W Lau, J Yong, M Eng

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading